SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: phoenix_rising who wrote (1397)8/4/2015 6:10:49 PM
From: mokelumne river  Read Replies (2) of 2026
 
Just to put a fine point on the 6/15 announcement that RayVa enrollment was completed, that did not mean that the last patient had been treated. I had to reread the PR to understand that. Actual treatment of that last patient may have been weeks later. So I am not expecting RayVa Phase 2a results to be announced tomorrow at the conference call. Pascoe may say that the last patient was treated and the blinded data is now being analyzed by whoever does the analysis. Or maybe he will just reiterate that the results will be out in this the third quarter.

I think RayVa has little if any market recognition. Hope that changes with good results and an FDA green light on the Phase 2b.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News